184 related articles for article (PubMed ID: 27620476)
1. Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase.
Kundu S; Biukovic G; Grüber G; Dick T
Antimicrob Agents Chemother; 2016 Nov; 60(11):6977-6979. PubMed ID: 27620476
[TBL] [Abstract][Full Text] [Related]
2. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
Salifu EY; Agoni C; Olotu FA; Soliman MES
Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
[TBL] [Abstract][Full Text] [Related]
3. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of
Sarathy JP; Ragunathan P; Shin J; Cooper CB; Upton AM; Grüber G; Dick T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358589
[TBL] [Abstract][Full Text] [Related]
4. A systematic assessment of mycobacterial F
Wong CF; Lau AM; Harikishore A; Saw WG; Shin J; Ragunathan P; Bhushan S; Ngan SC; Sze SK; Bates RW; Dick T; Grüber G
FEBS J; 2021 Feb; 288(3):818-836. PubMed ID: 32525613
[TBL] [Abstract][Full Text] [Related]
5. The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis.
Lu P; Villellas C; Koul A; Andries K; Lill H; Bald D
J Antibiot (Tokyo); 2014 Dec; 67(12):835-7. PubMed ID: 24916895
[No Abstract] [Full Text] [Related]
6. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.
Guo H; Courbon GM; Bueler SA; Mai J; Liu J; Rubinstein JL
Nature; 2021 Jan; 589(7840):143-147. PubMed ID: 33299175
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal mode of action of bedaquiline.
Hards K; Robson JR; Berney M; Shaw L; Bald D; Koul A; Andries K; Cook GM
J Antimicrob Chemother; 2015 Jul; 70(7):2028-37. PubMed ID: 25754998
[TBL] [Abstract][Full Text] [Related]
8. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
Divita KM; Khatik GL
Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
[TBL] [Abstract][Full Text] [Related]
9. Insights into the Physiology and Metabolism of a Mycobacterial Cell in an Energy-Compromised State.
Patil V; Jain V
J Bacteriol; 2019 Oct; 201(19):. PubMed ID: 31285242
[No Abstract] [Full Text] [Related]
10. The NMR solution structure of Mycobacterium tuberculosis F-ATP synthase subunit ε provides new insight into energy coupling inside the rotary engine.
Joon S; Ragunathan P; Sundararaman L; Nartey W; Kundu S; Manimekalai MSS; Bogdanović N; Dick T; Grüber G
FEBS J; 2018 Mar; 285(6):1111-1128. PubMed ID: 29360236
[TBL] [Abstract][Full Text] [Related]
11. Diarylquinolines target subunit c of mycobacterial ATP synthase.
Koul A; Dendouga N; Vergauwen K; Molenberghs B; Vranckx L; Willebrords R; Ristic Z; Lill H; Dorange I; Guillemont J; Bald D; Andries K
Nat Chem Biol; 2007 Jun; 3(6):323-4. PubMed ID: 17496888
[TBL] [Abstract][Full Text] [Related]
12. Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline.
Krah A; Ragunathan P; Bond PJ; Grüber G
Biochem Biophys Res Commun; 2024 Jan; 690():149249. PubMed ID: 38000294
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel Mycobacterial F-ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines.
Hotra A; Ragunathan P; Ng PS; Seankongsuk P; Harikishore A; Sarathy JP; Saw WG; Lakshmanan U; Sae-Lao P; Kalia NP; Shin J; Kalyanasundaram R; Anbarasu S; Parthasarathy K; Pradeep CN; Makhija H; Dröge P; Poulsen A; Tan JHL; Pethe K; Dick T; Bates RW; Grüber G
Angew Chem Int Ed Engl; 2020 Aug; 59(32):13295-13304. PubMed ID: 32337801
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure.
Wu C; Luo J; Wu M; Meng F; Cai Z; Chen Y; Sun T
Med Chem; 2020; 16(5):703-714. PubMed ID: 31203803
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines.
Courbon GM; Palme PR; Mann L; Richter A; Imming P; Rubinstein JL
EMBO J; 2023 Aug; 42(15):e113687. PubMed ID: 37377118
[TBL] [Abstract][Full Text] [Related]
16. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
18. A tale of two inhibitors: diarylquinolines and squaramides.
Chen J; Ekiert DC
EMBO J; 2023 Aug; 42(15):e114912. PubMed ID: 37435707
[TBL] [Abstract][Full Text] [Related]
19. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.
Segala E; Sougakoff W; Nevejans-Chauffour A; Jarlier V; Petrella S
Antimicrob Agents Chemother; 2012 May; 56(5):2326-34. PubMed ID: 22354303
[TBL] [Abstract][Full Text] [Related]
20. ATP Synthase, an Emerging Target in TB Drug Discovery: Review of SAR and Clinical Pharmacology of Diarylquinoline Inhibitors.
Dhulap A; Banerjee P
Curr Drug Targets; 2021; 22(11):1207-1221. PubMed ID: 33480344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
